4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

Compare

488 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FDMT Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Molecular Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FDMT Stock 12 Month Forecast

Average Price Target

$33.83

▲(289.75% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $33.83 with a high forecast of $45.00 and a low forecast of $26.00. The average price target represents a 289.75% change from the last price of $8.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,13.163076923076924,15.816153846153846,18.46923076923077,21.122307692307693,23.775384615384617,26.42846153846154,29.081538461538464,31.734615384615388,34.38769230769231,37.040769230769236,39.69384615384616,42.346923076923076,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,12.303846153846154,14.097692307692308,15.891538461538461,17.685384615384613,19.479230769230767,21.27307692307692,23.066923076923075,24.86076923076923,26.654615384615383,28.448461538461537,30.24230769230769,32.036153846153844,{"y":33.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,11.701538461538462,12.893076923076922,14.084615384615384,15.276153846153846,16.46769230769231,17.65923076923077,18.85076923076923,20.042307692307695,21.233846153846155,22.425384615384615,23.61692307692308,24.80846153846154,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$33.83

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Caufield

H.C. Wainwright

$36

Buy

314.75%

Upside

Reiterated

12/18/25

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN)

Jonathan Miller

Evercore ISI

$45

Buy

418.43%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and 4D Molecular Therapeutics (NASDAQ: FDMT)

Daniel Giraldo

Bank of America Securities

$31

Buy

257.14%

Upside

Reiterated

12/17/25

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT)

Judah Frommer

Morgan Stanley

Hold

―

Reiterated

12/17/25

4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating

Geulah Livshits

Chardan Capital

$26

Buy

199.54%

Upside

Reiterated

11/10/25

Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)

Lisa Walter

RBC Capital

$26→$32

Buy

268.66%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (NASDAQ: EVAX), 4D Molecular Therapeutics (NASDAQ: FDMT) and Arcturus Therapeutics (NASDAQ: ARCT)

Gena Wang

Barclays

$38→$33

Buy

280.18%

Upside

Reiterated

11/10/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Barclays

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

10/15/25

Salveen Richter

Goldman Sachs

$44→$38

Buy

337.79%

Upside

Reiterated

08/12/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Goldman Sachs

Kelly Shi

Jefferies

$51→$40

Buy

360.83%

Upside

Reiterated

02/10/25

4D Molecular Therapeutics (FDMT) PT Lowered to $40 at JefferiesJefferies analyst Nalin Tejavibulya lowered the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $40.00 (from $51.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Caufield

H.C. Wainwright

$36

Buy

314.75%

Upside

Reiterated

12/18/25

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN)

Jonathan Miller

Evercore ISI

$45

Buy

418.43%

Upside

Reiterated

12/18/25

Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and 4D Molecular Therapeutics (NASDAQ: FDMT)

Daniel Giraldo

Bank of America Securities

$31

Buy

257.14%

Upside

Reiterated

12/17/25

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT)

Judah Frommer

Morgan Stanley

Hold

―

Reiterated

12/17/25

4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating

Geulah Livshits

Chardan Capital

$26

Buy

199.54%

Upside

Reiterated

11/10/25

Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)

Lisa Walter

RBC Capital

$26→$32

Buy

268.66%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (NASDAQ: EVAX), 4D Molecular Therapeutics (NASDAQ: FDMT) and Arcturus Therapeutics (NASDAQ: ARCT)

Gena Wang

Barclays

$38→$33

Buy

280.18%

Upside

Reiterated

11/10/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Barclays

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

10/15/25

Salveen Richter

Goldman Sachs

$44→$38

Buy

337.79%

Upside

Reiterated

08/12/25

4D Molecular Therapeutics (FDMT) Gets a Buy from Goldman Sachs

Kelly Shi

Jefferies

$51→$40

Buy

360.83%

Upside

Reiterated

02/10/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 4D Molecular Therapeutics

1 Month

xxx

Success Rate

8/17 ratings generated profit

Average Return

+4.68%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of +4.68% per trade.

3 Months

xxx

Success Rate

7/17 ratings generated profit

Average Return

+1.65%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of +1.65% per trade.

1 Year

Matthew CaufieldH.C. Wainwright

Success Rate

12/24 ratings generated profit

Average Return

+8.67%

reiterated a buy rating 4 days ago

Copying Matthew Caufield's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.67% per trade.

2 Years

xxx

Success Rate

7/17 ratings generated profit

Average Return

-3.12%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of -3.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FDMT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FDMT has received 14 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. FDMT average Analyst price target in the past 3 months is 33.83.

Each month's total comprises the sum of three months' worth of ratings.

FDMT Financial Forecast

FDMT Earnings Forecast

Next quarter’s earnings estimate for FDMT is -$0.53 with a range of -$1.05 to $0.42. The previous quarter’s EPS was -$1.01. FDMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.

FDMT Sales Forecast

Next quarter’s sales forecast for FDMT is $27.00M with a range of $0.00 to $85.00M. The previous quarter’s sales results were $90.00K. FDMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.

FDMT Stock Forecast FAQ

What is FDMT’s average 12-month price target, according to analysts?

Based on analyst ratings, 4D Molecular Therapeutics’s 12-month average price target is 33.83.

What is FDMT’s upside potential, based on the analysts’ average price target?

4D Molecular Therapeutics has 289.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FDMT a Buy, Sell or Hold?

4D Molecular Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is 4D Molecular Therapeutics’s price target?

The average price target for 4D Molecular Therapeutics is 33.83. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 289.75% Increase from the current price of $8.68.

What do analysts say about 4D Molecular Therapeutics?

4D Molecular Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of FDMT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

FDMT Analyst Ratings

FDMT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 4D Molecular Therapeutics

FDMT Analyst Recommendation Trends

FDMT Financial Forecast

FDMT Earnings Forecast

FDMT Sales Forecast

FDMT Stock Forecast FAQ

Detailed List of Analyst Forecasts